Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets

 
• By Joseph Haas
  
DealWatch_1200x675
Insitro and Gilead ink NASH deal; updates from Catalent, Boehringer, PureTech, Fibrocell
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business